AU2021403606B2 - Chemical compounds useful for inhibiting nav1.8 voltage-gated sodium channels and treating nav1.8 mediated diseases - Google Patents

Chemical compounds useful for inhibiting nav1.8 voltage-gated sodium channels and treating nav1.8 mediated diseases Download PDF

Info

Publication number
AU2021403606B2
AU2021403606B2 AU2021403606A AU2021403606A AU2021403606B2 AU 2021403606 B2 AU2021403606 B2 AU 2021403606B2 AU 2021403606 A AU2021403606 A AU 2021403606A AU 2021403606 A AU2021403606 A AU 2021403606A AU 2021403606 B2 AU2021403606 B2 AU 2021403606B2
Authority
AU
Australia
Prior art keywords
pain
compound
pharmaceutically acceptable
disorder
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021403606A
Other languages
English (en)
Other versions
AU2021403606A9 (en
AU2021403606A1 (en
Inventor
Jie GUANG
David Glenn WASHBURN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of AU2021403606A1 publication Critical patent/AU2021403606A1/en
Publication of AU2021403606A9 publication Critical patent/AU2021403606A9/en
Application granted granted Critical
Publication of AU2021403606B2 publication Critical patent/AU2021403606B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2021403606A 2020-12-18 2021-12-16 Chemical compounds useful for inhibiting nav1.8 voltage-gated sodium channels and treating nav1.8 mediated diseases Active AU2021403606B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063127341P 2020-12-18 2020-12-18
US63/127,341 2020-12-18
PCT/EP2021/086101 WO2022129283A1 (en) 2020-12-18 2021-12-16 Chemical compounds useful for inhibiting nav1.8 voltage-gated sodium channels and treating nav1.8 mediated diseases

Publications (3)

Publication Number Publication Date
AU2021403606A1 AU2021403606A1 (en) 2023-06-22
AU2021403606A9 AU2021403606A9 (en) 2024-06-27
AU2021403606B2 true AU2021403606B2 (en) 2024-11-14

Family

ID=79025144

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021403606A Active AU2021403606B2 (en) 2020-12-18 2021-12-16 Chemical compounds useful for inhibiting nav1.8 voltage-gated sodium channels and treating nav1.8 mediated diseases

Country Status (13)

Country Link
EP (1) EP4262978A1 (enExample)
JP (1) JP2024502231A (enExample)
KR (1) KR20230121827A (enExample)
CN (1) CN116710463A (enExample)
AU (1) AU2021403606B2 (enExample)
CA (1) CA3202328A1 (enExample)
CL (1) CL2023001750A1 (enExample)
CO (1) CO2023008049A2 (enExample)
IL (1) IL303795A (enExample)
MX (1) MX2023007244A (enExample)
PH (1) PH12023551406A1 (enExample)
SA (1) SA523441263B1 (enExample)
WO (1) WO2022129283A1 (enExample)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201604477SA (en) * 2013-12-13 2016-07-28 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
GB201322602D0 (en) * 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
KR102714561B1 (ko) * 2017-05-16 2024-10-10 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 중수소화 피리돈 아미드 및 이의 프로드럭
MA56398A (fr) * 2019-06-27 2022-05-04 Glaxosmithkline Ip Dev Ltd Composés 2,3-dihydroquinazoline en tant qu'inhibiteurs de nav1.8

Also Published As

Publication number Publication date
CA3202328A1 (en) 2022-06-23
IL303795A (en) 2023-08-01
JP2024502231A (ja) 2024-01-18
SA523441263B1 (ar) 2025-01-07
MX2023007244A (es) 2023-06-29
CO2023008049A2 (es) 2023-06-30
CL2023001750A1 (es) 2024-01-19
PH12023551406A1 (en) 2024-01-22
WO2022129283A1 (en) 2022-06-23
KR20230121827A (ko) 2023-08-21
AU2021403606A1 (en) 2023-06-22
CN116710463A (zh) 2023-09-05
EP4262978A1 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
JP7701880B2 (ja) NaV1.8阻害剤としての2,3-ジヒドロキナゾリン化合物
KR102469161B1 (ko) Rho-관련 단백질 키나아제 억제제, Rho-관련 단백질 키나아제 억제제를 함유하는 약학 조성물, 제조 방법 및 약학 조성물의 용도
JPWO2015163435A1 (ja) 新規2−アミノ−ピリジン及び2−アミノ−ピリミジン誘導体及びその医薬用途
CA2992622A1 (en) Cgrp receptor antagonists
US20240083896A1 (en) Nitrogen Containing 2,3-Dihydroquinazolinone Compounds as Nav1.8 Inhibitors
US20250084112A1 (en) Chemical Compounds Useful for Inhibiting Nav1.8 Voltage-Gated Sodium Channels and Treating Nav1.8 Mediated Diseases
JP2017078039A (ja) 新規2−アミノ−ピリジン又は2−アミノ−ピリミジン誘導体を有効成分として含有する医薬組成物
CA3202328A1 (en) Chemical compounds useful for inhibiting nav1.8 voltage-gated sodium channels and treating nav1.8 mediated diseases
US20230416287A1 (en) Chemical Compounds
RU2833870C2 (ru) СОЕДИНЕНИЯ 2,3-ДИГИДРОХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ NaV1.8
WO2020206119A1 (en) Process for making pyridone amides and prodrugs thereof useful as modulators of sodium channels

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)